Trifecta-Lung cfDNA-MMDx Study
Launched by UNIVERSITY OF ALBERTA · Apr 18, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Trifecta-Lung cfDNA-MMDx Study is a clinical trial aimed at understanding how certain levels of genetic material (called dd-cfDNA) in the blood relate to specific antibodies in lung transplant recipients. The study will also evaluate a testing system called the Molecular Microscope® (MMDx), which helps doctors assess the health of lung transplants through special biopsies. This research is important because it could improve the way doctors monitor lung transplant patients and help ensure their long-term success.
To participate in this study, you must be an adult aged 65 to 74 who has received a lung transplant. Unfortunately, individuals who are unable to give informed consent, those who have received multiple organ transplants, cancer patients, and pregnant women cannot take part in this trial. If you join, you can expect to undergo blood tests and biopsies as part of the study, which will help researchers gather valuable information about lung health after transplantation. Your participation could contribute to advancing care for future lung transplant patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult, Older adult
- Exclusion Criteria:
- • Patients will be excluded from the study if they decline participation Are unable to give informed consent. Recipients of multiple organs, cancer patients and pregnant women
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Melbourne, , Australia
Vienna, , Austria
Edmonton, Alberta, Canada
Prague, , Czechia
Edmonton, Alberta, Canada
Prague, , Czechia
Dallas, Texas, United States
Gainesville, Florida, United States
New York, New York, United States
Tampa, Florida, United States
Patients applied
Trial Officials
Philip F Halloran, MD PhD
Principal Investigator
Alberta Transplant Applied Genomics Centre, University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported